Colombo Joshua R, Wein Richard O
Department of Otolaryngology, Head and Neck Surgery, Tufts Medical Center, Boston, MA, USA.
Ther Clin Risk Manag. 2014 May 28;10:395-404. doi: 10.2147/TCRM.S46041. eCollection 2014.
Medullary thyroid cancer is uncommon and patients typically present with advanced disease. Treatment options for patients with progressive, metastatic medullary thyroid cancer had been limited until recently. Tyrosine kinase inhibitors have garnered increasing interest in this subset of patients. The US Food and Drug Administration recently approved cabozantinib, a tyrosine kinase inhibitor, after promising results were shown in a large Phase III clinical trial. This review summarizes the clinical pharmacology, clinical trials, and safety data for cabozantinib and concludes with a discussion of possible future directions for the treatment of medullary thyroid cancer.
甲状腺髓样癌并不常见，患者通常就诊时已处于疾病晚期。直到最近，进展性、转移性甲状腺髓样癌患者的治疗选择一直有限。酪氨酸激酶抑制剂在这类患者中引起了越来越多的关注。美国食品药品监督管理局最近批准了酪氨酸激酶抑制剂卡博替尼，此前一项大型III期临床试验显示了有前景的结果。本综述总结了卡博替尼的临床药理学、临床试验及安全性数据，并以讨论甲状腺髓样癌治疗可能的未来方向作为结尾。
